AstraZeneca Pharma India has received a final assessment order under the Income Tax Act, 1961 for the assessment year 2022-23. The assessment order, received on January 16, 2026, pertains to legacy transfer pricing and corporate tax issues. The company intends to challenge the order by filing an appeal with the Income-tax Appellate Tribunal (ITAT).
Assessment Order Details
AstraZeneca Pharma India announced that it has received a final assessment order under section 143(3) read with section 144C(13) and 144(B) of the Income Tax Act, 1961. This order relates to the assessment year 2022-23 and was received on January 16, 2026.
Nature of the Assessment
The assessment involves adjustments related to legacy transfer pricing and certain corporate tax issues. The original draft order was previously disclosed on March 19, 2025. The company believes the order warrants further challenge.
Company’s Response
AstraZeneca plans to contest the assessment order by filing an appeal with the Income-tax Appellate Tribunal (ITAT). The company will pursue all available legal avenues to address the concerns raised in the assessment order.
Financial Implications
The assessment order includes a claim of Rs. 11.88 crores (approximately), excluding interest and penalty. The overall financial impact remains subject to the outcome of the appeal. Further details and a complete assessment of the impact will be conducted as the matter progresses.
Source: BSE
